NZ772009A - Use of riluzole prodrugs to treat alzheimer’s disease - Google Patents

Use of riluzole prodrugs to treat alzheimer’s disease

Info

Publication number
NZ772009A
NZ772009A NZ772009A NZ77200919A NZ772009A NZ 772009 A NZ772009 A NZ 772009A NZ 772009 A NZ772009 A NZ 772009A NZ 77200919 A NZ77200919 A NZ 77200919A NZ 772009 A NZ772009 A NZ 772009A
Authority
NZ
New Zealand
Prior art keywords
disease
treat alzheimer
riluzole
riluzole prodrugs
prodrugs
Prior art date
Application number
NZ772009A
Other languages
English (en)
Inventor
Vladimir Coric
Robert Berman
Irfan Qureshi
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of NZ772009A publication Critical patent/NZ772009A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ772009A 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer’s disease NZ772009A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701814P 2018-07-22 2018-07-22
PCT/US2019/042718 WO2020023324A1 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Publications (1)

Publication Number Publication Date
NZ772009A true NZ772009A (en) 2026-02-27

Family

ID=69181140

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ772009A NZ772009A (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer’s disease

Country Status (15)

Country Link
US (1) US12161633B2 (https=)
EP (1) EP3823616A4 (https=)
JP (2) JP2021530543A (https=)
KR (1) KR20210034621A (https=)
CN (1) CN112469408A (https=)
AU (1) AU2019310013B2 (https=)
BR (1) BR112021000768A2 (https=)
CA (1) CA3107215A1 (https=)
EA (1) EA202190308A1 (https=)
IL (1) IL280177B2 (https=)
MX (2) MX2021000515A (https=)
NZ (1) NZ772009A (https=)
PH (1) PH12021550043A1 (https=)
SG (1) SG11202100385YA (https=)
WO (1) WO2020023324A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230027189A (ko) * 2020-06-24 2023-02-27 바이오하벤 테라퓨틱스 리미티드 강박 장애를 치료하기 위한 조성물 및 방법
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity
WO2022178425A1 (en) * 2021-02-22 2022-08-25 Yale University Targeted bifunctional degraders
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214663B2 (en) * 2000-06-14 2007-05-08 Medarex, Inc. Tripeptide prodrug compounds
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
EP3079692A4 (en) 2013-12-09 2017-10-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
WO2016085998A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
RS62915B1 (sr) * 2015-03-03 2022-03-31 Biohaven Therapeutics Ltd Prolekovi riluzola i njihova primena
WO2017201502A1 (en) * 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
WO2018031707A1 (en) * 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
AU2019223014B2 (en) * 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity

Also Published As

Publication number Publication date
CN112469408A (zh) 2021-03-09
EP3823616A1 (en) 2021-05-26
US20210290599A1 (en) 2021-09-23
SG11202100385YA (en) 2021-02-25
EA202190308A1 (ru) 2021-05-19
BR112021000768A2 (pt) 2021-05-11
WO2020023324A1 (en) 2020-01-30
IL280177A (en) 2021-03-01
EP3823616A4 (en) 2022-05-04
IL280177B1 (en) 2024-09-01
IL280177B2 (en) 2025-01-01
MX2021000515A (es) 2021-06-08
US12161633B2 (en) 2024-12-10
KR20210034621A (ko) 2021-03-30
CA3107215A1 (en) 2020-01-30
PH12021550043A1 (en) 2021-09-20
JP2021530543A (ja) 2021-11-11
AU2019310013A1 (en) 2021-02-11
AU2019310013B2 (en) 2025-01-02
JP2025093952A (ja) 2025-06-24
MX2024010655A (es) 2024-09-11

Similar Documents

Publication Publication Date Title
NZ772009A (en) Use of riluzole prodrugs to treat alzheimer’s disease
PH12020551425A1 (en) Rimegepant for cgrp related disorders
ZA202002626B (en) Use of riluzole prodrugs to treat ataxias
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12021550443A1 (en) Pyridazinones and methods of use thereof
MX385332B (es) Moduladores de ror-gamma.
PH12019501896A1 (en) Therapeutic dendrimers
EP3708168A3 (en) Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia
PH12021550671A1 (en) Prodrugs of cgrp antagonists
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
PH12020500666A1 (en) Pladienolide compounds and their use
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
EA201790315A1 (ru) Модуляторы x-рецепторов печени
MY196979A (en) Method of treating disease by auricular anesthesia of cranial nerves
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
MX2016008968A (es) Compuestos organicos.
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
MX2019003720A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
EP4537846A3 (en) Anavex2-73 for the treatment of alzheimer s disease
EA202091162A1 (ru) Применение пролекарств рилузола для лечения атаксии